National Institute for Health and Care Excellence has recommended capivasertib for advanced breast cancer NHS patients
The Institute of Cancer Research shared a post on LinkedIn:
“BREAKING NEWS:
NICE – National Institute for Health and Care Excellence has recommended capivasertib for advanced breast cancer NHS patients.
The decision makes the targeted drug available, in combination with hormone therapy, for treating some patients with the most common type of breast cancer.
Capivasertib was discovered by AstraZeneca subsequent to a collaboration with Astex Pharmaceuticals (and its collaboration with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited).
We’re so proud of all of our scientists who were involved in the history of this drug – from the fundamental research to the phase III clinical trial which led to this positive decision.
We hope this new treatment option will improve the lives of thousands of NHS patients in England and Wales.
More post featuring The Institute of Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023